Maria J. Dominguez
University of Vigo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maria J. Dominguez.
Hypertension | 2003
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Maria J. Dominguez; Manuel Covelo; José R. Fernández; Artemio Mojón; Jose E. Lopez
Abstract—This study investigated the administration time–dependent antihypertensive efficacy of valsartan, an angiotensin II receptor blocker. We studied 90 subjects (30 men and 60 women), 49.0±14.3 (mean±SD) years of age with stage 1 to 2 essential hypertension; they were randomly assigned to receive valsartan (160 mg/d) as a monotherapy either on awakening or at bedtime. Blood pressure was measured by ambulatory monitoring every 20 minutes during the day and every 30 minutes at night for 48 consecutive hours before and after 3 months of treatment. Physical activity was simultaneously monitored every minute by wrist actigraphy to accurately calculate the diurnal and nocturnal means of blood pressure on a per-subject basis. The highly significant blood pressure reduction after 3 months of treatment with valsartan (P <0.001) was similar for both treatment times (17.0 and 11.3 mm Hg reduction in the 24-hour mean of systolic and diastolic blood pressure with morning administration and 14.6 and 11.4 mm Hg reduction with bedtime administration; P >0.174 for treatment time effect). Valsartan administration at bedtime as opposed to on wakening resulted in a highly significant average increase by 6% (P <0.001) in the diurnal-nocturnal ratio of blood pressure; this corresponded to a 73% relative reduction in the number of nondipper patients. The findings confirm that valsartan efficiently reduces blood pressure throughout the entire 24 hours, independent of treatment time. They also suggest that time of treatment can be chosen according to the dipper status of a patient to optimize the effect of antihypertensive therapy, an issue that deserves further investigation.
Chronobiology International | 2004
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Maria J. Dominguez; Manuel Covelo; José R. Fernández; Maria J. Fontao; Jose E. Lopez
Previous studies have shown that a single nighttime dose of standard doxazosin, an α-adrenergic antagonist, reduces blood pressure (BP) throughout the 24 h. We investigated the administration-time-dependent effects of the new doxazosin gastrointestinal therapeutic system (GITS) formulation. We studied 91 subjects (49 men and 42 women), 56.7 ± 11.2 (mean ± SD) yrs of age with grade 1–2 essential hypertension; 39 patients had been previously untreated, and the remaining 52 had been treated with two antihypertensive medications with inadequate control of their hypertension. The subjects of the two groups, the monotherapy and polytherapy groups, respectively, were randomly assigned to receive the single daily dose of doxazosin GITS (4 mg/day) either upon awakening or at bedtime. BP was measured by ambulatory monitoring every 20 min during the day and every 30 min at night for 48 consecutive hours just before and after 3 months of treatment. After 3 months of doxazosin GITS therapy upon awakening, there was a small and nonstatistically significant reduction in BP (1.8 and 3.2 mm Hg in the 24 h mean of systolic and diastolic BP in monotherapy; 2.2 and 1.9 mm Hg in polytherapy), mainly because of absence of any effect on nocturnal BP. The 24 h mean BP reduction was larger and statistically significant (6.9 and 5.9 mm for systolic and diastolic BP, respectively, in monotherapy; 5.3 and 4.5 mm Hg in polytherapy) when doxazosin GITS was scheduled at bedtime. This BP-lowering effect was similar during both the day and nighttime hours. Doxazosin GITS ingested daily on awakening failed to provide full 24 h therapeutic coverage. Bedtime dosing with doxazosin GITS, however, significantly reduced BP throughout the 24 h both when used as a monotherapy and when used in combination with other antihypertensive pharmacotherapy. Knowledge of the chronopharmacology of doxazosin GITS is key to optimizing the efficiency of its BP-lowering effect, and this must be taken into consideration when prescribing this medication to patients.
Circulation | 2003
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Jose E. Lopez; Jose R. Fernandez; Artemio Mojón; Maria J. Dominguez; Manuel Covelo
Background—A seasonal variation with higher values in winter has been previously reported in plasma fibrinogen, a recognized marker of the potential risk of myocardial infarction and stroke. The lack of nocturnal decline in blood pressure has also been associated with an increase in cardiovascular events. Accordingly, we have compared the yearly variation of plasma fibrinogen in dipper and nondipper hypertensive patients. Methods and Results—We studied 1006 stage 1 to 2 hypertensive patients (482 men and 524 women, 53.0±13.4 years of age). Blood pressure was measured every 20 minutes during the day and every 30 minutes at night for 48 consecutive hours. Physical activity was simultaneously evaluated at 1-minute intervals with a wrist actigraph. A blood sample was collected on the same day before starting blood pressure monitoring. The circannual variation of fibrinogen was established for all patients as well as for subgroups of dippers and nondippers (n=513; nocturnal blood pressure decline <10%) by multiple-component analysis. For the whole group of patients, fibrinogen was characterized by a highly significant seasonal variation (P <0.001) with a mean value of 318 mg/dL, double circannual amplitude (extent of predictable change along the year) of 40 mg/dL, and time of peak value in February. Throughout the year, the nondippers showed higher plasma fibrinogen levels than did the dippers (P <0.001). Conclusions—The elevated plasma fibrinogen levels in nondipper patients appear to be directly related to their increased risk in vascular events, which are more prominent during the late winter months.
Hypertension | 2003
Ramon C. Hermida; Diana E. Ayala; Carlos Calvo; Jose E. Lopez; Jose R. Fernandez; Artemio Mojón; Maria J. Dominguez; Manuel Covelo
Abstract— Previous studies on the potential influence of aspirin on blood pressure have not taken into consideration the chronopharmacological effects of nonsteroidal anti‐inflammatory drugs. This pilot study investigates the effects of aspirin on blood pressure in untreated hypertensive patients who received aspirin at different times of the day according to their rest‐activity cycle. We studied 100 untreated patients with mild hypertension (34 men and 66 women), 42.5±11.6 (mean±SD) years of age, randomly divided into 3 groups: nonpharmacological hygienic‐dietary recommendations; the same recommendations and aspirin (100 mg/d) on awakening; or the same recommendations and aspirin before bedtime. Blood pressure was measured every 20 minutes during the day and every 30 minutes at night for 48 consecutive hours before and after 3 months of intervention. The circadian pattern of blood pressure in each group was established by population multiple‐component analysis. After 3 months of nonpharmacological intervention, there was a small, nonsignificant reduction of blood pressure (<1.1 mm Hg;P >0.341). There was no change in blood pressure when aspirin was given on awakening (P =0.229). A highly significant blood pressure reduction was, however, observed in the patients who received aspirin before bedtime (decrease of 6 and 4 mm Hg in systolic and diastolic blood pressure, respectively;P <0.001). Results indicate a statistically significant administration time–dependent effect of low‐dose aspirin on blood pressure in untreated patients with mild hypertension. The influence of aspirin on blood pressure demonstrated in this study indicates the need to quantify and control for aspirin effects in patients using this drug in combination with antihypertensive medication.
American Journal of Hypertension | 2009
Ramon C. Hermida; Luisa Chayán; Diana E. Ayala; Artemio Mojón; Maria J. Dominguez; Maria J. Fontao; Rita Soler; Ignacio Alonso; José R. Fernández
BACKGROUND There is a marked association between metabolic syndrome (MS) and increased cardiovascular risk. Moreover, nondipping (patients with <10% decline in the asleep relative to the awake blood pressure (BP) mean) has also been associated with increased cardiovascular morbidity and mortality. METHODS We investigated the association between MS and impaired nocturnal BP decline in 1,770 nondiabetic, untreated hypertensive patients (824 men and 946 women), 48.7 +/- 13.2 years of age. BP was measured by ambulatory monitoring for 48 h to increase reproducibility of the dipping pattern. Physical activity was simultaneously monitored every minute by wrist actigraphy. RESULTS MS was present in 42.4% of the patients. The prevalence of a nondipper BP profile was significantly higher in patients with MS (46.1% vs. 37.5% in patients without MS, P < 0.001). Patients with MS were characterized by significant elevations in uric acid (5.9 mg/dl vs. 5.2 mg/dl, P < 0.001), fibrinogen (314 mg/dl vs. 304 mg/dl, P = 0.021), and globular sedimentation rate (13.8 mm vs. 11.6 mm, P < 0.001). Nondipping was significantly associated to the presence of MS in a multiple logistic regression model adjusted by other significant confounding factors, including age, serum creatinine, and cigarette smoking. The single most relevant factor in the definition of MS associated to nondipping was elevated waist perimeter. CONCLUSIONS This study documents a significant increase of a blunted nocturnal BP decline in patients with MS. Patients with MS were also characterized by elevated values of relevant markers of cardiovascular risk, including fibrinogen and globular sedimentation rate.
Medicina Clinica | 2003
Ramon C. Hermida; Diana E. Ayala; Carlos Calvo; Jose E. Lopez; José R. Fernández; Artemio Mojón; Maria J. Dominguez; Manuel Covelo
Fundamento y objetivos Los estudios previos sobre el posible efecto del acido acetilsalicilico(AAS) sobre la presion arterial no han tenido en cuenta los cambios en la farmacocinetica de lamedicacion antiinflamatoria no esteroidea en funcion de la hora de administracion del farmaco.El objetivo de este estudio piloto ha sido investigar los efectos del AAS sobre la presion arterialen pacientes con hipertension arterial esencial ligera, sin tratamiento antihipertensivo y que recibieronAAS a distintas horas del dia, en funcion de su ciclo de actividad y descanso. Pacientes y metodo Estudiamos a 64 pacientes con hipertension arterial esencial (24 varones),con una edad media (DE) de 43,5 (12,0) anos, que fueron aleatorizados a tres grupos de tratamiento:grupo 1, con recomendaciones higienicodieteticas sin intervencion farmacologica; grupo2, con recomendaciones higienicodieteticas y AAS (100 mg/dia) a la hora de levantarse, ygrupo 3, con recomendaciones higienicodieteticas y AAS (100 mg/dia) en el momento de acostarse.La presion arterial se monitorizo en cada paciente durante 48 h consecutivas antes ydespues de tres meses de intervencion. El patron circadiano de variacion de la presion arterialpara cada grupo de pacientes se establecio mediante analisis poblacional de componentesmultiples. Los parametros circadianos calculados para cada grupo antes y despues de la intervencionse compararon con una prueba no parametrica pareada. Resultados Despues de los tres meses de tratamiento, en el grupo 1 se produjo una leve y nosignificativa reduccion de la presion arterial ( Conclusiones Los resultados indican que la administracion de AAS en pacientes con hipertensionesencial tiene un significativo efecto hipotensor, que es claramente dependiente de lahora de administracion del farmaco. Este efecto del AAS sobre la presion arterial implica la necesidadde tenerlo en cuenta cuando se utilice AAS en los pacientes hipertensos que, ademas,reciben medicacion antihipertensiva.
Medicina Clinica | 2003
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Jose E. Lopez; José R. Fernández; Artemio Mojón; Maria J. Dominguez; Manuel Covelo
Fundamento y objetivo El incremento de las concentraciones plasmaticas de fibrinogeno se consideraun factor de riesgo de enfermedad arteriosclerotica, fundamentalmente cardiopatia coronaria y accidentecerebrovascular. En estudios previos se ha descrito una variacion estacional en el fibrinogeno,con valores mas altos en los meses mas frios. Por otra parte, la ausencia de descenso nocturno en lapresion arterial se ha asociado tambien a un aumento de acontecimientos cardiovasculares. En consecuencia,hemos cuantificado la variacion estacional del fibrinogeno en pacientes hipertensos esenciales,clasificados en funcion del descenso nocturno de la presion arterial. Pacientes y metodo Estudiamos a 577 pacientes con hipertension arterial esencial ligera-moderada(254 varones), con una edad media (DE) de 53,8 (13,8) anos, reclutados a lo largo de dos anos. Lapresion arterial se monitorizo cada 20 min de dia y cada 30 min por la noche, durante 48 h consecutivas.La actividad fisica se monitorizo simultaneamente cada minuto con un actigrafo de muneca. Elfibrinogeno se determino a partir de un analisis de sangre realizado el mismo dia de inicio de la monitorizacion.La variacion estacional del fibrinogeno plasmatico se determino para todos los sujetos asicomo para los subgrupos de dippers (n = 287) y no dippers (n = 290; pacientes con un descenso nocturnoinferior al 10% con respecto a la media diurna de la presion sistolica) mediante analisis decomponentes multiples longitudinal. Resultados Para el total de pacientes hipertensos estudiados, el fibrinogeno presenta una variacion estacionalaltamente significativa (p Conclusiones La elevacion de la concentracion de fibrinogeno en pacientes no dipper podria apoyarlos resultados que asocian la ausencia de descenso nocturno en la presion arterial a un aumento deacontecimientos cardiovasculares, de acuerdo con la correlacion existente entre la variacion circanualdel fibrinogeno y la variacion estacional comunicada para acontecimientos coronarios.
American Journal of Hypertension | 2004
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Maria J. Dominguez; Manuel Covelo; Artemio Mojón; Jose R. Fernandez; Jose E. Lopez
tigated the administration time-dependent antihypertensive efficacy of valsartan in elderly hypertensive patients. We studied 50 elderly patients with grade 1–2 essential hypertension (20 men), 67.0 0.8 years of age, randomly assigned to receive single daily valsartan monotherapy (160 mg/day) either on awakening or before bedtime. BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 hours before and after 3 months of therapeutic intervention. Physical activity was also monitored every minute by wrist actigraphy, and the information used to determine diurnal and nocturnal means of BP for each patient according to individual resting time. There was a highly significant BP reduction after 3 months of valsartan (P 0.001), similar for both treatment times (14.1 and 7.7 mm Hg reduction in the 24-hour mean of systolic and diastolic BP after valsartan on awakening; 14.7 and 8.2 mm Hg when valsartan was administered before bedtime). The day/night ratio measured as the nocturnal decline of BP relative to the diurnal mean was unchanged after valsartan on awakening ( 2.1 and 0.6 for systolic and diastolic BP; P 0.184). This ratio was highly significantly increased (6.1 and 6.3 for systolic and diastolic BP, P 0.001) when valsartan was administered before bedtime. The reduction of nocturnal mean was, therefore, significantly larger after valsartan before bedtime (P 0.032). Results indicate that, at either the time of administration, 160 mg/day valsartan efficiently reduce BP for the whole 24 hours. In elderly hypertensive patients, characterized by a diminished nocturnal decline in BP, dosing time with valsartan might be chosen at bedtime, for improved efficacy during the nocturnal resting hours, and the potential reduction in cardiovascular risk associated to the normalized day/ night ratio.
American Journal of Hypertension | 2004
Ramon C. Hermida; Diana E. Ayala; Carlos Calvo; Maria J. Dominguez; Manuel Covelo; Artemio Mojón; José R. Fernández; Maria J. Fontao; Rita Soler; Jose E. Lopez
calculated from the original series and those obtained from shorter series up to data obtained at 2-hour intervals. Sensitivity, however, was reduced by 9%, and specificity by a very high 44%, when diagnosis was based on data sampled at 20–30 min intervals for the first 24 hours. This prospective study demonstrates that sampling for just 24 hours is insufficient for a proper diagnosis of hypertension based on the highly reproducible tolerance-hyperbaric test. Moreover, sampling rate can be greatly reduced, for increased patient compliance, by expanding the monitoring span for at least 2 consecutive days. Results also corroborate that the proper estimation of any parameter derived from a BP series (such as the HBI) is markedly dependent on duration of sampling, but not on sampling rate.
American Journal of Hypertension | 2001
Ramon C. Hermida; Carlos Calvo; Diana E. Ayala; Jose E. Lopez; José R. Fernández; Maria J. Dominguez; Artemio Mojón; C. Martıénez; Ignacio Alonso; Maria J. Fontao; Manuel Covelo
Background The lack of nocturnal decline in blood pressure has been associated with an increase in end-organ damage and cardiovascular events, although results remain controversial, partly because of the inability to reproduce correctly, over time, the classification of patients into dippers and non-dippers. Moreover, the non-dipping status has been frequently related to an increase in nocturnal activity, differences in quality of sleep, or both. Objective To assess the relationship between activity and blood pressure in patients with hypertension. Methods We studied 306 mild-to-moderately hypertensive patients (130 men), 53.7 ± 14.0 years of age (mean ± SD). Blood pressure and heart rate were measured for 48 consecutive hours, at 20-min intervals during the day and at 30-min intervals at night, using an ambulatory device, and physical activity was simultaneously evaluated at 1-min intervals by wrist actigraphy. Circadian parameters of blood pressure, heart rate and activity established by population multiple-components analysis were compared between dippers and non-dippers, by non-parametric testing. Diurnal and nocturnal means of blood pressure and activity were computed for each patient according to individual resting hours determined by actigraphy, and compared among groups by analysis of variance. Results Despite highly statistically significant differences between dippers and non-dippers with respect to nocturnal means and in each hourly nightly mean of blood pressure, there were no differences between them for the same parameters during activity, whether or not the patients were receiving medication at the time of monitoring. The average duration of sleep and the 24-h mean and standard deviation of activity were also similar between the groups. Conclusions The highly significantly different circadian variation in blood pressure between dippers and non-dippers with essential hypertension is not related to a significant increase in nocturnal physical activity. Differences in blood pressure could, however, be related to the absence of 24-h therapeutic coverage in most non-dipper patients receiving antihypertensive medication.